IDIBELL and ICO researchers, awarded by the Children’s Tumor Foundation

Villanueva_Lazaro_1 (1)

The selected project is entitled “Targeting NF‐1 associated MPNST with aurora kinase inhibitors” and is awarded with the maximum compensation in their category, with $50,000. It is intended for the use of aurora kinase inhibitors to treat animal models generated in the ICO and IDIBELL premises.

Scroll to Top